Aminoglycoside Resistance: Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases

Jun Ichi Wachino; Yohei Doi; Yoshichika Arakawa

doi:10.1016/j.idc.2020.06.002

Aminoglycoside Resistance: Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases

Jun Ichi Wachino, Yohei Doi, Yoshichika Arakawa

Microbiology

Research output: Contribution to journal › Review article › peer-review

47 Citations (Scopus)

Abstract

The clinical usefulness of aminoglycosides has been revisited as an effective choice against β-lactam–resistant and fluoroquinolone-resistant gram-negative bacterial infections. Plazomicin, a next-generation aminoglycoside, was introduced for the treatment of complicated urinary tract infections and acute pyelonephritis. In contrast, bacteria have resisted aminoglycosides, including plazomicin, by producing 16S ribosomal RNA (rRNA) methyltransferases (MTases) that confer high-level and broad-range aminoglycoside resistance. Aminoglycoside-resistant 16S rRNA MTase-producing gram-negative pathogens are widespread in various settings and are becoming a grave concern. This article provides up-to-date information with a focus on aminoglycoside-resistant 16S rRNA MTases.

Original language	English
Pages (from-to)	887-902
Number of pages	16
Journal	Infectious Disease Clinics of North America
Volume	34
Issue number	4
DOIs	https://doi.org/10.1016/j.idc.2020.06.002
Publication status	Published - 12-2020

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.idc.2020.06.002

Cite this

@article{6f53d8b7436b47d6bd576354513e8e25,

title = "Aminoglycoside Resistance: Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases",

abstract = "The clinical usefulness of aminoglycosides has been revisited as an effective choice against β-lactam–resistant and fluoroquinolone-resistant gram-negative bacterial infections. Plazomicin, a next-generation aminoglycoside, was introduced for the treatment of complicated urinary tract infections and acute pyelonephritis. In contrast, bacteria have resisted aminoglycosides, including plazomicin, by producing 16S ribosomal RNA (rRNA) methyltransferases (MTases) that confer high-level and broad-range aminoglycoside resistance. Aminoglycoside-resistant 16S rRNA MTase-producing gram-negative pathogens are widespread in various settings and are becoming a grave concern. This article provides up-to-date information with a focus on aminoglycoside-resistant 16S rRNA MTases.",

author = "Wachino, {Jun Ichi} and Yohei Doi and Yoshichika Arakawa",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = dec,

doi = "10.1016/j.idc.2020.06.002",

language = "English",

volume = "34",

pages = "887--902",

journal = "Infectious Disease Clinics of North America",

issn = "0891-5520",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Aminoglycoside Resistance

T2 - Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases

AU - Wachino, Jun Ichi

AU - Doi, Yohei

AU - Arakawa, Yoshichika

PY - 2020/12

Y1 - 2020/12

N2 - The clinical usefulness of aminoglycosides has been revisited as an effective choice against β-lactam–resistant and fluoroquinolone-resistant gram-negative bacterial infections. Plazomicin, a next-generation aminoglycoside, was introduced for the treatment of complicated urinary tract infections and acute pyelonephritis. In contrast, bacteria have resisted aminoglycosides, including plazomicin, by producing 16S ribosomal RNA (rRNA) methyltransferases (MTases) that confer high-level and broad-range aminoglycoside resistance. Aminoglycoside-resistant 16S rRNA MTase-producing gram-negative pathogens are widespread in various settings and are becoming a grave concern. This article provides up-to-date information with a focus on aminoglycoside-resistant 16S rRNA MTases.

AB - The clinical usefulness of aminoglycosides has been revisited as an effective choice against β-lactam–resistant and fluoroquinolone-resistant gram-negative bacterial infections. Plazomicin, a next-generation aminoglycoside, was introduced for the treatment of complicated urinary tract infections and acute pyelonephritis. In contrast, bacteria have resisted aminoglycosides, including plazomicin, by producing 16S ribosomal RNA (rRNA) methyltransferases (MTases) that confer high-level and broad-range aminoglycoside resistance. Aminoglycoside-resistant 16S rRNA MTase-producing gram-negative pathogens are widespread in various settings and are becoming a grave concern. This article provides up-to-date information with a focus on aminoglycoside-resistant 16S rRNA MTases.

UR - http://www.scopus.com/inward/record.url?scp=85091873144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091873144&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2020.06.002

DO - 10.1016/j.idc.2020.06.002

M3 - Review article

C2 - 33011054

AN - SCOPUS:85091873144

SN - 0891-5520

VL - 34

SP - 887

EP - 902

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

IS - 4

ER -

Aminoglycoside Resistance: Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this